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Abstract: Parkinson disease is typically treated with L-3,4-dihydroxyphenylalanine (or levodopa) co-
prescribed with concentration stabilizers to prevent undesired motor fluctuations. However, the benefi-
cial role of the chronic combined therapy on disease progression has not been thoroughly explored. We
hypothesized that tolcapone, a catechol-O-methyl-transferase inhibitor, co-administered with levodopa
may offer beneficial long-term disease-modifying effects through its dopamine stabilization actions. Here,
we followed vesicular monoamine transporter 2-deficient and wild-type mice treated twice daily per os
with vehicle, levodopa (20 mg/kg), tolcapone (15 mg/kg) or levodopa (12.5 mg/kg) + tolcapone (15
mg/kg) for 17 weeks. We assessed open field, bar test and rotarod performances at baseline and ev-
ery 4th week thereafter, corresponding to OFF-medication weeks. Finally, we collected coronal sections
from the frontal caudate-putamen and determined the reactivity level of dopamine transporter. Vesicular
monoamine transporter 2-deficient mice responded positively to chronic levodopa + tolcapone interven-
tion in the bar test during OFF-periods. Neither levodopa nor tolcapone interventions offered significant
improvements on their own. Similarly, chronic levodopa + tolcapone intervention was associated with
partially rescued dopamine transporter levels, whereas animals treated solely with levodopa or tolcapone
did not present this effect. Interestingly, 4-month progression of bar test scores correlated significantly
with dopamine-transporter-label density. Overall, we observed a moderate functional and histopatho-
logical improvement effect by chronic dopamine replacement when combined with tolcapone in vesicular
monoamine transporter 2-deficient mice. Altogether, chronic stabilization of dopamine levels by catechol-
O-methyl-transferase inhibition, besides its intended immediate actions, arises as a potential long-term
beneficial approach during the progression of Parkinson disease.
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1. Introduction (we don’t have a title and an abstract page?) 1 
Oral administration of L-3,4-dihydroxyphenylalanine (levodopa or L-DOPA), the 2 
endogenous precursor of dopamine (DA), combined with a DA decarboxylase 3 
inhibitor, such as benserazide hydrochloride or carbidopa, is currently the most 4 
effective, tolerable, and therefore broadly used treatment for patients with Parkinson 5 
disease (PD). However, the use of L-DOPA is burdened with several limitations, 6 
including short-time bioavailability of each dose due to extensive peripheral 7 
metabolism. In addition, there is the assumption that long-term dopaminergic 8 
stimulation with L-DOPA facilitates the occurrence of motor fluctuations with 9 
dyskinesia (Connolly and Lang, 2014; Jenner et al., 2011). The latter have been 10 
closely related to disease duration, and treatment duration and dosage (Schrag and 11 
Quinn, 2000).  12 
Recent recommendations, therefore, suggested to evaluate alternative 13 
pharmacotherapies than L-DOPA for treatment initiation in certain patients, to avoid 14 
long-term levodopa-related motor complications (Connolly and Lang, 2014). On the 15 
other hand, an elegant delayed-start trial in early PD patients recently found similar 16 
rates of dyskinesia and L-DOPA-related motor fluctuations at 80 weeks when 17 
comparing a group treated with L-DOPA for 80 weeks and another group placebo-18 
treated for 40 weeks followed by 40 weeks of L-DOPA treatments (Verschuur et al., 19 
2019). The authors concluded that L-DOPA treatment duration may not havebear a 20 
disease-modifying effect, at least in relation to motor fluctuations.  21 
In addition to treatment duration and dosing, the pattern of DA receptor stimulation 22 
has been associated with the emergence of dyskinesias: continuous dopaminergic 23 
treatment - either with long-acting DA-receptor agonists or continuous L-DOPA 24 
 2 
infusions - is related to fewer motor fluctuations duringdyskinesias and motor 25 
fluctuations, as for instance evidenced in a primate PD model on-medication (Bibbiani 26 
et al., 2005). This finding has driven the search for strategies to reduce pulsatile DA 27 
receptor stimulation (Nyholm, 2006; Olanow and Schapira, 2013; Chondrogiorgi et al., 28 
2014). The goal of the STRIDE-PD study was to examine whether adding entacapone, 29 
an inhibitor of catechol-O-methyltransferase (COMT), to L-DOPA reduces the 30 
development of dyskinesia, as this approach increases L-DOPA’s half-life and 31 
smoothens its serum concentrations, i.e. leads to a mildly enhanced continuous 32 
stimulation of postsynaptic DA receptors (Stocchi and Olanow, 2004; Stocchi et al., 33 
2010). The study was negative, but the authors rightfully discussed the outcome’s 34 
relation with the study design, as it provided higher L-DOPA dose equivalents in the 35 
entacapone group. In factOn the other hand, experimental animal models of LIDs (L-36 
DOPA induced dyskinesias) suggest that the loss of nigrostriatal DA neurons may be 37 
the cause for or at least contribute to the development of such abnormal involuntary 38 
movements (Cenci, 2014). All in allAltogether, despite the extensive and negative 39 
STRIDE study, it is still unclear whether COMT inhibition during prolongedlong-term 40 
dopaminergic stimulation at bioavailable L-DOPA equivalent doses offers any long-41 
lasting and/or disease-modifying effect in PD, such aswhich would be best reflected 42 
by deceleration of nigrostriatal DA denervation, and which in turn, might have a 43 
beneficialn impact on LIDs onset and severity.  44 
Tolcapone, a selective and reversible COMT inhibitor penetrating the blood-brain 45 
barrier (Guldberg and Marsden, 1975; Backstrom et al., 1989; Kopin, 1985; Nagatsu 46 
and Sawada, 2009a; Kiss et al., 2010), offers a potent and sustained inhibition in vivo 47 
(Zürcher et al., 1990; Bonifácio et al., 2007). It is widely accepted that central COMT 48 
inhibition by tolcapone reduces degradation of L-DOPA to 3-O-methyldopa, thus 49 
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widening its therapeutic window, while further prolonging L-DOPA effectiveness in the 50 
brain by reducing DA metabolism to homovanillic acid (Kurth and Adler, 1998; 51 
Kaakkola, 2000; Zeuner et al., 2019).Besides peripherally inhibiting L-DOPA 52 
metabolism, tolcapone further inactivates central COMT and reduces degradation of 53 
extrasynaptic or diffused DA to 3-methoxytyramine (Kurth and Adler, 1998; Kaakkola, 54 
2000; Zeuner et al., 2019), thus, stabilizing its bioavailable synaptic concentration and 55 
modulating dopaminergic transmission of presynaptic and postsynaptic neurons 56 
(Chen et all., 2011). Ultimately, continuous postsynaptic dopaminergic signaling by 57 
tempered and stable DA levels will possibly lead to long-term clinical and pathological 58 
amelioration. Notwithstanding, tolcapone was associated with increases in liver 59 
enzymes in a dose-dependent manner (Longo et al., 2016). Peripheral inhibition of 60 
soluble-COMT may be at least in part, the main underlying cause of tolcapone‐induced 61 
hepatotoxicity: uncoupling of oxidative phosphorylation and the subsequent reduction 62 
in mitochondrial energy (Haasio et al., 2002).  63 
The cause of L-DOPA-induced motor fluctuations is not entirely understood. Apart 64 
from contributions from disturbed neurotransmission, the best available evidence 65 
suggests that progressive degeneration of DA-producing cells in the substantia nigra 66 
is mandatory (Leta et al., 2019). In parallel, degeneration of dopaminergic terminals 67 
along with aberrant processing of exogenously administered L-DOPA lead to 68 
imbalanced striatal DA levels, causing motor fluctuations (Niccolini et al., 2015). For 69 
instance, the link of dyskinesia with dopaminergic denervation is supported by findings 70 
in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) addicts and in rodents with 71 
complete nigral lesions (Winkler et al., 2002; Langston, 2017), although these studies 72 
lacked a necessary longitudinal perspective. Altogether, there appears to be a strong 73 
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association between the degree of nigrostriatal denervation/neurodegeneration and 74 
the expression of dyskinesia (Di Monte et al., 2000). 75 
Ultimately contributing to neurodegeneration as well, chronicChronic use of L-DOPA 76 
generates several toxic molecules (Paul and Borah, 2016), responsible for increased 77 
predisposition to vascular disease and accelerated disease progression (Müller, 78 
2011). One such metabolite is homocysteine (Hcy), the level of which increases in the 79 
plasma of PD patients ultimately generatingcomposes a high risk for vascular diseases 80 
and dementia (Kocer et al., 2016). Furthermore, Hcy exerts a neurotoxic action and 81 
may participate in the mechanisms of neurodegeneration, such as DNA damage, 82 
excitotoxicity, oxidative stress and neuronal degeneration (Bhattacharjee and Borah, 83 
, calcium accumulation, and apoptosis (Zoccolella et al., 2006a). Several studies have 84 
shown that higher concentration of Hcy in PD is related to long-term administration of 85 
L-DOPA (Lamberti et al., 2005; Ibrahimagic et al., 2016). Therapeutic approaches 86 
against hyperhomocysteinemiahyperhomocysteinaemia include COMT inhibition, - 87 
reducing S‐adenosylhomocysteine by blocking COMT’s O-methylation of L-DOPA, - 88 
and in turn lowering its subproduct, Hcy  Hcy, and the risk of associated co-morbidities 89 
and neurodegenerative burden (Paul and Borah, 2016). ; Zoccolella et al., 2006b).  90 
To investigate COMT inhibition in DA replacement therapy in a preclinical setting, we 91 
used avesicular monoamine transporter 2-deficient (VMAT2-LO) mice. This genetic 92 
animal model of PD that encompasses many of the progressive motor and non-motor 93 
symptoms described in patients, particularly in aged subjects. During our window of 94 
pharmacological intervention, from 14 to 18 months of age, these animals show 95 
gradually decreased motor function, as well as the hallmark neurpathology of the 96 
disease, such as the vesicular monoamine transporter 2-deficient (VMAT2-LO) 97 
miceage-dependent decline of DAT expression and activity, contributing to neuronal 98 
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degeneration in older animals (Taylor et al., 20112009). We specifically aimed to 99 
examine whether adding tolcapone to L-DOPA, with consecutively mildly-enhanced 100 
prolonged dopaminergic stimulation at bioavailable L-DOPA equivalent doses, 101 
reduces the progression of motor deficits during OFF-medication and striatal 102 
neuropathology – which is reportedly linkedthe cause for the development to 103 
dyskinesias – and motor deficits progression.. In addition, as a secondary outcome, 104 
we examineexamined whether adding this COMT inhibitorcombining tolcapone with 105 
prolonged L-DOPA treatment indeed reduces plasmatic levels of total Hcy (tHcy). ) 106 
and, possibly, contributes to an overall ameliorated condition. 107 
 108 
2. Materials and Methods 109 
2.1 Animals 110 
In total, we included 21 VMAT2-LO and 23 VMAT2-WT fourteen-month-old male mice 111 
with C57BL/6 genetic background. The VMAT2-LO line, obtained from the group of 112 
Gary Miller at Emory University, USA (Caudle et al., 2007), expresses only ~5% of the 113 
VMAT2 protein (Mooslehner et al., 2001). We single-housed all animals with food and 114 
water provided ad libitum until completion of the studies. We kept the animals on a 12-115 
hour light/dark cycle and constant temperature (21 - 22°C) and relative humidity (30%). 116 
We weighed all mice daily and acclimated them to the experimental room before 117 
behavioral testing.  We carried our studies approved by both local and federal Swiss 118 
authorities under the license n. ZH 205/2012. 119 
 120 
2.2 Study design 121 
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We aimed to determine whether combined L-DOPA + tolcapone administration, in 122 
comparison to single drug administration, had an OFF-medication (i.e. after drug 123 
wash-out) beneficial effect on functional behavioral and histological disease hallmarks. 124 
Thus, we intended to initiate interventions after the onset of the majority of motor 125 
symptoms (functional behavioral markers) and when dopamine transporter (DAT, 126 
functional histological marker) levels were already affected, but preceding the age 127 
when neurodegeneration was first reported, indicated by tyrosine hydroxylase cell loss 128 
in the substantia nigra. We based the temporal window and duration of the treatments 129 
on the disease dynamics reported earlier for this model (Taylor et al., 2011).  130 
At 14 months of age, we began the chronic 17-week intervention with one week of 131 
baseline behavioral testing followed by four identical periods consisting of 3 weeks of 132 
pharmacological treatment (ON-period) plus 1 behavioral testing week (OFF-period) 133 
(Figure 1). We administered drugs per os twice daily at lights-on and 8 hours later. 134 
After the last behavioral testing week (17th week, OFF-period, after 5.5 days wash-out 135 
of all drugs), we obtained plasma samples to quantify liver transaminases,  euthanized 136 
the animals and collected their brains and livers for later evaluations. 137 
 138 
2.3 Pharmacological interventions  139 
We grouped all mice into four treatment sets: vehicle (NaCl 0.9%, ‘-V’); L-140 
DOPA/benserazide (20.0 mg/kg: Madopar® 125 mg, Roche Pharma AG, Switzerland, 141 
‘-L’), tolcapone (15.0 mg/kg: Tasmar® 100 mg, MEDA Pharma GmHB, Switzerland, ‘-142 
T’); and a 1:1 solution of L-DOPA/benserazide (12.5 mg/kg) and tolcapone (15.0 143 
mg/kg: ‘-LT’). We aimed for equalized concentrations of L-DOPA/benserazide at the 144 
synaptic level in both -L and -LT groups, by multiplying the ordinary L-DOPA dosage 145 
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(12.5 mg/kg) by 1.6, in order to achieve the same DA bioavailability in the -L group 146 
(20.0 mg/kg) (Bonifácio et al., 2015). Each mouse received a total of 120 doses 147 
complemented with a daily portion of wet-food (water and crushed chow) in addition 148 
to the regular chow. 149 
 150 
2.4 Behavioral tests  151 
We performed all tests in OFF-medication weeks (start 3.5 days after the last 152 
treatment episode), during the light period. We conducted all tests in 2 consecutive 153 
days, following the same order and at the same time of day.  154 
To assess locomotor activity, we used the open field test (Bello et al., 2011): 4 identical 155 
plexiglas boxes (46x46x40 cm) and a video camera connected to an automated 156 
tracking system (EthoVision XT 9.0, Noldus, Germany). We habituated animals to the 157 
setup for 15 minutes prior to the testing day. During the testing trial, we allowed each 158 
animal to freely explore the arena for 30 minutes while recording spontaneous 159 
horizontal distance travelled. 160 
We used the bar test to assess catalepsy, a syndrome often attributed to dopaminergic 161 
antagonism or failure of DA neurotransmission, and interpreted to reflect bradykinesia, 162 
rigidity and abnormal posture (de Ryck et al., 1980; Alvarez-Cervera et al., 2005; Noain 163 
et al., 2013). Briefly, we placed the animals sitting on the working bench over their hind 164 
paws and grabbing an elevated acrylic bar with their front paws. We considered a trial 165 
valid when the animal remained grabbing the bar at least 2 seconds and up to 180 166 
seconds.  167 
To examine motor coordination, we performed a standard mouse rotarod test 168 
(UgoBasile©, Italy) (Avale et al., 2004), set at constant speed. Three hours before the 169 
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testing session, we subjected the animals to a 10-minute training. During the testing 170 
phase, we placed the animals onto the rotating treadmill until a maximum time of 180 171 
seconds. 172 
 173 
2.5 Food intake  174 
To examine the potential influence of feeding behavior and/or body weight on 175 
pharmacodynamics, we performed a modified food-intake test during the 15th week 176 
(ON-period) in all animals. Briefly, we removed all dry food-pellets from the cages and, 177 
for 4 days, we only presented wet-food. We weighed the cups daily and corrected the 178 
results for food evaporation. 179 
 180 
2.6 Total homocysteine quantification  181 
To confirm whether tolcapone is indeed helpful in reducing Hcy levels during 182 
prolonged L-DOPA replacement, we assayed standard ELISA determinations of tHcy 183 
in plasma of VMAT2-WT animalstHcy using a mouse homocysteine kit (Crystal Chem, 184 
Catalog #80444, USA) as per manufacturer’s protocol. The absorbance readings from 185 
VMAT2-LO animals samples were increased up to 20-fold across all groups compared 186 
to VMAT2-WT-V animals, and therefore, considered untrustworthy given the accuracy 187 
limits of the commercial kit. VMAT2-LO mice have been reported to present increased 188 
levels of cysteinationfree cysteinyl-DOPA and cysteinyl-DOPAC adducts, derivatives 189 
of proteinsthe reaction of DOPA and DOPAC quinones with free cysteine (Caudle et 190 
al., 2007),). The specificity of the commercial kit to Hcy in plasma samples also 191 
containing abnormally high levels of cysteinyl isomers was not assured by the 192 
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provider, for which levels of tHcy could not be specifically determined in this genotype 193 
(data not shown). 194 
 195 
2.7 Liver enzyme quantification  196 
To test whether our heaviest drug regime (-LT), as proxy of all other treatments (Longo 197 
et al., 2016), negatively affected liver function in VMAT2-LO mice, we measured 198 
plasma levels of aspartate transaminase (AST) and alanine transaminase (ALT), in 199 
VMAT2-LO-V and VMAT2-LO-LT, by standard blood test. Two samples from the 200 
VMAT2-LO-LT group were found hemolyzed at the time of analysis, and were 201 
discarded by advice of the Center for Laboratory Medicine and Pathology (USZ).  202 
 203 
2.8 Full-body perfusion  204 
For histological analyses, we sacrificed all animals by trans-cardiac perfusion at 18 205 
months of age (exsanguination using ice-cold phosphate-buffered-saline followed by 206 
perfusion of freshly prepared ice-cold 4% paraformaldehyde (Sigma Aldrich). 207 
Immediately after fixation, we harvested the brains, post-fixed, dehydrated, quick-froze 208 
in dry ice and stored them at -80°C. Later full-brain sectioning was done at 30 µm 209 
thickness in freezing-staged microtome. Due to freezing issues with the microtome, 210 
we discarded two VMAT2-LO-V brains from further analysis.  211 
 212 
2.9 Immunohistochemistry, microscopy and color-density quantification 213 
We included every fourth coronal section from the rostral portion of the striatum. 214 
Briefly, after washing the sections in tris-buffered-saline, we blocked endogenous 215 
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peroxidase activity by incubating sections in 2% H2O2 for 30 min. We incubated free-216 
floating sections with a monoclonal rat anti-DAT antibody (#MAB369; Merck; 1:500) 217 
overnight at 4°C. Next, we incubated the sections in a biotinylated goat anti-rat 218 
secondary antibody (#AB97057, Abcam, 1:1000) for 2 hours at RT followed by avidin-219 
biotin complex for 1.5 hours at RT. We developed sections with 0.025% 3,3′-220 
diaminobenzidine (DAB) and 0.05% H2O2 in tris-buffered-saline. 221 
Using an Axio Imager M2 microscope (Karl Zeiss, Jena, Germany), we acquired 222 
images from the coronal section with the highest signal intensity for quantification of 223 
DAT stained terminals (Ruifrok and Johnston, 2001). We obtained full-section images 224 
with a 2.5x objective, and further analyzed them with ImageJ (version 1.47j, National 225 
Institutes of Health, USA). Briefly, we processed all images using the hematoxylin-226 
3,3′-diaminobenzidine vector, in order to obtain the DAB exclusive quantification 227 
panel. From each section, the signal estimate is the average color intensity, which is 228 
proportional to the concentration of the stain, of bilateral measurements in the striatum. 229 
All values were corrected for area and background-noise, the last by subtracting the 230 
intensity in the cortex. As per the Lambert-Beer law, we calculated DAT optical density 231 
(OD, p.d.u.) according to the formula OD= log(255/ mean_intensity_striatum) – 232 
log(255/ mean_intensity_cortex).  233 
 234 
2.10 Statistics  235 
We conducted nested 2-way ANOVA to compare the effects of all pharmacological 236 
interventions on performances in open field test, bar test and rotarod, on the last OFF-237 
period of the protocol (Figure 1, 17th week, treatment(genotype)). Levene’s test for 238 
equality of variances was found to be violated for the time of immobility in the bar test 239 
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(F(7,36)=3.95, **p=.003), and for latency to fall in the rotarod test (F(7,36) = 15.86, 240 
***p<.001), therefore data was ranked. On other instances, t-statistics not assuming 241 
homogeneity of variance were corrected with Welch’s test. Error bars in the figures 242 
represent ±SEM. Raw data will be made available upon reasonable request. 243 
 244 
3. Results 245 
3.1 Improved progression of bradykinesia and postural stability scores OFF-246 
medication in VMAT2-LO mice chronically co-administered with L-DOPA and 247 
tolcapone 248 
Determining the effect of different chronic therapeutic interventions on motor behavior 249 
after washing out medication is a suitable instrument for assessing disease-modifying 250 
effects. To determine the progression of motor deficits in pharmacologically intervened 251 
VMAT2-LO mice and VMAT2-WT controls, we used the open field, bar and rotarod 252 
tests, with a particular emphasis on so-called axial symptoms like postural 253 
impairments, as such signs are considered particularly important for measuring motor 254 
progression (Schreiner et al., 2019). 255 
At baseline, VMAT2-LO mice performed significantly worse in all three motor tests as 256 
compared to VMAT2-WT controls, that is impaired locomotor activity (unpaired 257 
t(42)=6.03, ***p<.001; Figure 2a), increased time of immobility (Welch’s t(20)=5.23, 258 
***p<.001; Figure 2b) and poorer motor coordination (unpaired t(42)=4.17, ***p<.001; 259 
Figure 2c). 260 
None of the pharmacological regimes counteracted the motor deficits in VMAT2-LO 261 
mice on the last assessment week, evidenced by impaired OFF-medication 262 
performance compared to VMAT2-WT animals in all tests. In the open field, 263 
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collectively, VMAT2-LO showed reduced locomotor activity compared to VMAT2-WT 264 
(nested 2-way ANOVA, treatment(genotype), F(4,36)=10.43, ***p<.001, Figure 2d) 265 
despite all treatments. For catalepsy or immobility measures, VMAT2-LO animals 266 
maintained significantly longer latency for initiation of movement than VMAT2-WT 267 
controls (nested 2-way ANOVA of ranked cases, treatment(genotype), F(4,36)=23.06, 268 
***p<.001, Figure 2e), however non-vehicle subjects presented slightly better marks 269 
compared to vehicle animals within each genotype. Concerning motor coordination, 270 
symptoms in VMAT2-LO remained far from VMAT2-WT in the last testing week 271 
(nested 2-way ANOVA of ranked cases, treatment(genotype), F(4,36)=34.45, 272 
***p<.001, Figure 2f). Adding tolcapone to L-DOPA did not significantly changed 273 
performance when compared to -L-DOPA alone or -vehicle treated VMAT2-LO 274 
animals (Tukey post hoc comparison, L*LT and V*LT, p>.999). 275 
The results from the last behavioral assessment poorly reflect the longitudinal 276 
perspective of 17-weeks of progressive behavior: groups present high variability and 277 
low statistical power at the last protocol-week as well as in the other OFF-periods (5th, 278 
9th and 13th weeks). When analyzing the global motor progression, from baseline to 279 
endpoint, in relation to the treatments (comparison of slopes of linear robust-fittings 280 
from each subject’s scores), the progressive worsening in the bar test performance 281 
experienced by VMAT2-LO-LT mice appeared mitigated when compared to VMAT2-282 
LO-L, (unpaired t(8.43)=4.24, **p=.003, Figure 2k). Alternatively, the improved 283 
performance in the bar test could be explained by prolonged efficacy of dopaminergic 284 
stimulation by the addition of tolcapone, with a clinical effect even days after the last 285 
medication intake. Apart from this isolated finding, progression of the other motor 286 
variables was similar between different treatments, again with high intra- and inter-287 
variability (Figure 2g-l).  288 
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 289 
3.2 VMAT2-LO mice co-administered with L-DOPA and tolcapone had rescued striatal 290 
dopamine transporter levels compared to vehicle-treated transgenic mice   291 
DAT quantification in striatal tissue is a widely established marker of functional integrity 292 
of the DA system and was previously used to describe disease progression in VMAT2-293 
LO mice (Caudle et al., 2007; Taylor et al., 2009). We estimated DAT reactivity in the 294 
striatum (Figure 3a) of VMAT2-WT-V and all VMAT2-LO groups. VMAT2-LO-V mice 295 
presented reduced DAT signal strength compared to VMAT2-WT-V controls (Welch’s 296 
t(29.86)=2.43, *p=.022, Figure 3b), consistent with an ongoing functional decay in 297 
integrity of the striatal dopaminergic system in the mutants (Caudle et al., 2007). 298 
Remarkably, VMAT2-LO-LT mice presented a partially rescued level of DAT 299 
immunoreactivity compared to VMAT2-LO-V (one-way(Welch’s ANOVA, Brown-300 
Forsythe FW(3,69)=4.83, **31.43)=9.185, ***p=.004<.001, Figure 3c, d), indicating a 301 
significantly less deteriorated histopathological status (Tukeycompared to VMAT2-LO-302 
V (Games-Howell’s post hoc comparison, V*LT, ***p=.004033, Figure 3d). The 303 
observations between VMAT2-LO-V and VMAT2-LO-T (p>.999=.994), and VMAT2-304 
LO-V and VMAT2-LO-L and VMAT2-LO-LT mice (p=.142450) were statistically similar 305 
(Figure 3d). VMAT2-WT are statistically equal across all groups (Kruskal-Wallis test, 306 
H(3)=.098, p=.992, Figure 3e, f). 307 
 308 
3.3 Improved immobility scores are associated with rescued neuropathological status 309 
in VMAT2-LO mice treated with L-DOPA and tolcapone 310 
There is an association between progression of motors and non-motor symptoms and 311 
neuropathological status in both PD patients and animal models (Giasson et al., 2002; 312 
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Braak et al., 2003). To determine whether the immunoreactivity level of a functional 313 
integrity striatal marker predicts well motor ability in the bar test, we calculated a 314 
Pearson correlation between striatal DAT optical density and the bradykinesia 315 
progression index (slope over the scores of all time points for the time of immobility in 316 
the bar test) during OFF-medication in VMAT2-LO mice (Figure 4a). We found a 317 
significant correlation (Pearson’s, r(17)=-0.50, *p=.015), which could suggest an 318 
association between the effect of tolcapone-mediated steadier bioavailability of L-319 
DOPA and improved motor performance progression in this model. This link was 320 
visually confirmed in an exploratory group-based clustering across the correlated 321 
factors, including all mutant groups and the VMAT2-WT-V group as reference (Figure 322 
4b). This figure reveals that the VMAT2-LO-LT individuals (green) are closer 323 
positioned to the VMAT2-WT-V (black) centroid, overall reflecting that combined 324 
treatment with tolcapone provides behavioral and immunohistochemical findings that 325 
are closest to those of healthy animals.      326 
 327 
3.4 Food intake upon different treatments in VMAT2-LO mice 328 
VMAT2-LO mice present a distinct phenotype compared to VMAT2-WT littermates, 329 
thus, we characterized the feeding behavior of all animals in ON-medication. We 330 
assayed a tightly-controlled protocol and found a treatment-independent food-intake 331 
behavior in VMAT2-LO mice in respect to VMAT2-WT animals (two-way ANOVA, 332 
F(3,37)=0.19, genotype*treatment interaction, p=.906, Figure 5a), indicating that 15 333 
weeks of different pharmacological regimes did not differentially affect feeding 334 
behavior and, possibly, feeding-related confounders on behavior. However, VMAT2-335 
LO animals appeared to eat significantly more than VMAT2-WT controls in respect to 336 
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their body weight (two-way ANOVA, F(1,37)=18.36, genotype main effect, ***p<.001, 337 
Figure 5a). 338 
 339 
3.5 Effect of chronic combined administration of L-DOPA and tolcapone on plasma 340 
levels of tHcy and hepatic enzymes 341 
In agreement with previous evidence (Miller et al., 2003), we found that administration 342 
of L-DOPA increased the levels of tHcy in plasma and pushed them over the maximum 343 
standard concentration (one-way ANOVA F(3,18)=3.49, *p=.037, Figure 5b) when 344 
compared to vehicle animals (Tukey post hoc test, *p=.038). As expected, vehicle and 345 
tolcapone administration alone did not result in increased tHcy generation. Notably, 346 
stabilizing the bioavailability of L-DOPA with tolcapone appeared to restore tHcy 347 
plasma levels to normal values (Tukey post hoc test, p=.865, Figure 5b). Normal liver 348 
function was assessed on the last week of treatment by measuring AST and ALT 349 
plasma levels from blood samples of VMAT2-LO-V and VMAT2-LO-LT, the last being 350 
considered the group with the heaviest drug regime. We found no differences in ALT 351 
(unpaired t(7)=1.49, p=.179, Figure 5c) and AST levels (unpaired t(7)=0.40, p=.703, 352 
Figure 5c), nor in the AST/ALT ratio (unpaired t(7)=0.98, p=.359, Figure 5d), 353 
indicating no detrimental effect of chronic drug interventions at the assayed dosages 354 
on their hepatic functionality.  355 
 356 
4. Discussion 357 
Whether a more continuous dopaminergic stimulation, in general, and via COMT 358 
inhibition, in particular, may reduce L-DOPA-induced motor complications has been a 359 
matter of debate, despite some important high-impact publications (Stocchi and 360 
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Olanow, 2004). Available studies in human PD patients and rodent PD models could 361 
not unambiguously confirm such an effect (Katsaiti and Nixon, 2018). In particular, the 362 
STRIDE-PD study applying entacapone and L-DOPA in PD patients did not reveal a 363 
disease-modifying effect, but this negative result was hypothesized to be linked to 364 
higher L-DOPA equivalents in the entacapone group (Stocchi et al., 2010). Thus, it is 365 
conceivable that a beneficial effect from continuous dopaminergic stimulation by 366 
COMT inhibition has been masked by higher L-DOPA concentrations at the receptor 367 
site (Picconi et al., 2008). Apart from DA imbalance at the effector site, no studies are 368 
available on the long-term histopathological effects of such a strategy, i.e. whether 369 
more continuous dopaminergic stimulation via COMT inhibition reduces 370 
neuropathological findings in PD subjects. 371 
From a behavioral point of view, we consider the present study as negative, as the 372 
main hypothesis – is adding a COMT inhibitor to pulsatile L-DOPA treatment 373 
neuroprotective? – could not be fully confirmed. In this line, the improved outcome on 374 
the bar test could merely reflect a prolonged efficacy of dopaminergic replacement 375 
with COMT inhibition rather than a disease-modifying effect, while other behavioral 376 
outcomes were similar between treatment groups. On the other hand, on an 377 
immunohistochemistry level, we observed rescued DAT levels in VMAT2-LO-LT mice, 378 
and no differences between vehicle- and L-DOPA- or tolcapone-treated animals. This 379 
result corroborates previous work in this animal model, finding no change in DAT 380 
expression after L-DOPA subchronic (what is this?) administration, although at an 381 
earlier age (Reveron et al., 2002). In contrast, DAT staining presented a statistical 382 
trend towards higher DAT reactivity in VMAT2-LO-LT when compared to VMAT2-LO-383 
L.was statistically similar between VMAT2-LO-L and VMAT2-LO-LT, yet this lack of a 384 
difference might be explained by insufficient power. Taken together, the behavioral 385 
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and immunohistochemical results might suggest that treating PD animals with L-386 
DOPA+tolcapone improves their functional prognosis and reduces signs of 387 
neurodegeneration.  388 
The main limitation of our study is the lack of assessment of multiple markers of 389 
neurodegeneration upon treatments. This shortcoming is related to the treatment 390 
window chosen for the study. While tyrosine hydroxilate neurons, likely the gold 391 
standard marker of dopaminergic system integrity, are reported to die at a later stage 392 
in VMAT2-LO animals (Taylor et al., 2011), altered synuclein deposition is found since 393 
early age in this model (own unpublished data). This temporal disparity between the 394 
two most conventional neurodegeneration markers in PD, rendered DAT the 395 
intermediate outcome of choice. Rescued DAT levels by combined treatment, 396 
however, is a pertinent outcome pointing to future reduced neurodegeneration in 397 
VMAT2-LO mice. This is based not only on the fact that DAT reflects progressive 398 
damage to the dopaminergic system, but also that it is fundamentally involved in the 399 
profound neurochemical alterations that precede nigral degeneration in this model 400 
(Miller et al., 1997; Caudle et al., 2007). The “dying back” hypothesis proposes that 401 
decreased DAT function and expression might stand as a reliable proxy for loss of 402 
striatal dopaminergic projections, and most importantly, as indicator of future damage 403 
to the dopaminergic perikarya in the substantia nigra (Burke and O’Malley, 2013). 404 
Interestingly, the deterioration of DAT expression and activity seen at the time of 405 
sacrifice in VMAT2-LO-V mice is, reportedly, not resulting from loss of fiber density 406 
(and concomitant cell death) nor alterations in DAT expression in the midbrain of these 407 
animals (Caudle et al., 2007). Lifetime intraneuronal compensatory mechanisms and 408 
interaction with DA quinones and reactive oxygen species may explain the decrease 409 
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in DAT observed in aged vehicle-treated animals (Whitehead et al., 2001). Add a 410 
limitation re the VMAT2 model, see R1? 411 
One possible read-out of this study, therefore, is that inhibiting COMT with tolcapone 412 
in conjunction with chronic L-DOPA treatment, thus preventing DA fluctuations in the 413 
brain, might reduce DAT decline and, consequently, future nigrostriatal 414 
neurodegeneration. The behavioral outcome could partially confirm this hypothesis 415 
insomuch as VMAT2-LO-LT mice were the only group presenting stabilized 416 
bradykinesia and postural stability scores. Still, we cannot exclude a prolonged effect 417 
of dopaminergic stimulation at the receptor site, due to the addition of tolcapone, as 418 
discussed above. Nevertheless, the statistically significant link between behavior and 419 
immunohistochemical findings might further corroborate this hypothesis: slower 420 
deterioration of bar test performance in L-DOPA-treated groups appear correlated with 421 
preserved striatal DAT density levels, particularly the group co-administrated with the 422 
COMT inhibitor, to near the extent seen in VMAT2-WT-V group.  423 
In relation to eventual confounders, it is worth to mention that there is no evidence of 424 
compensatory changes in VMAT2 expression (Reveron et al., 2002) and no 425 
exacerbated effect on the feeding behavior of the animals. Moreover, the present 426 
analysis was inconclusive on the tolcapone influence on tHcy levels in the transgenic 427 
animals, although tolcapone indeed reduced tHcy in VMAT2-WT-L animals. Lastly, we 428 
did not find signs of hepatotoxicity from chronic tolcapone administration, in line with 429 
early studies reporting harm of this drug only to very high administration dosages 430 
(Longo et al., 2016). 431 
 432 
4.1 Conclusions 433 
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Altogether, despite equaling L-DOPA concentrations, this study does not undoubtedly 434 
support the assumption that adding a central COMT inhibitor to L-DOPA therapy 435 
provides a neuroprotective effect compared to L-DOPA alone. Although the results 436 
here are believed to reflect the deceleration of nigrostriatal degeneration insofar the 437 
integrity of the dopaminergic terminals is concerned, further experiments targeting a 438 
later intervention window enclosing other functional and/or histopathologic deficits in 439 
this PD model could clarify whether combining a COMT inhibitor can be 440 
neuroprotective. Such an attempt would be most welcome, as the present study – 441 
even as considered overall negative regarding the study hypothesis – produced results 442 
which at least indicate that mildly enhanced continuous dopaminergic stimulation 443 
might reduce DAT decline and, consequently, future nigrostriatal neurodegeneration. 444 
From a clinical perspective, this finding would become relevant once there were strong 445 
clinical evidence supporting these preclinical insights. In other words, if large clinical 446 
delayed start design studies would confirm that smoothening L-DOPA fluctuations – 447 
be it with COMT inhibitors or with other strategies - decelerates the disease course, 448 
then clinical practice might shift towards adding a COMT inhibitor to L-DOPA plus 449 
benserazide/carbidopa in early PD patients. This seems particularly relevant as 450 
nowadays many neurologists shift back to initiate treatment with L-DOPA rather than 451 
dopamine agonists because of the many and potentially harmful side effects (i.e. 452 
impulse control disorders) of the latter.  453 
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Figure legends 689 
 690 
Figure 1. Experimental design and timeline. VMAT2 LO (n = 21) and WT (n = 23) 691 
mice were behaviorally tested at 14 months of age (baseline: BL), before starting a 692 
chronic regime of pharmacological interventions that lasted 17 weeks. Each treatment 693 
month consisted of 3 weeks of drug administration (‘ON’-medication, blue rectangles), 694 
plus 1 week of behavioral testing (‘OFF’-medication, grey rectangle). Each ON-695 
medication week consisted of 5 days of twice daily per os dosaging, at light onset and 696 
8 hours late, of saline (-V), L-DOPA (-L), tocalpone (-T) or L-DOPA+tolcapone (-LT). 697 
On the 15th ON-medication week, the food intake was assessed in all animals. After 698 
17 weeks on interventions, the mice were sacrificed (red marking) and blood and 699 
tissue samples collected for posterior evaluations. (AST – aspartate transaminase, 700 
ALT – alanine transaminase, tHcy – total homocysteine, DAT – dopamine transporter). 701 
 702 
Figure 2. Motor ability in response to chronic pharmacological interventions in 703 
VMAT2-LO mice. At baseline (BL), VMAT2-LO (n = 21) and VMAT2-WT control (n = 704 
23) drug naïve mice were behaviorally tested in 3 different motor domains: (a) 705 
locomotion (open field test), (b) body rigidity (bar test), and (c) coordination (rotarod 706 
test). In all three tests, VMAT2-LO mice performed significantly worse than VMAT2-707 
WT ((a) unpaired t(42)=6.03, ***p<.001; (b) Welch’s t(20)=4.56, ***p<.001; (c) 708 
unpaired t(42)=4.17, ***p<.001). At endpoint testing, after 16 weeks of interventions, 709 
all VMAT2-LO mice presented a marked behavioral impairment in all parameters 710 
explored, as compared to VMAT2-WT controls ((d) nested 2-way ANOVA, 711 
treatment(genotype), F(4,36)=10.43, ***p<.001; (e) nested 2-way ANOVA of ranked 712 
cases, treatment(genotype), F(4,36)=23.06, ***p<.001; (f) nested 2-way ANOVA of 713 
 32 
ranked cases, treatment(genotype), F(4,36)=34.45, ***p<.001). The progression of 714 
individual symptoms in VMAT2-LO mice in respect to the treatment received was 715 
analyzed in subsets: (g, h, i) -V vs -T treated VMAT2-LO animals were compared to 716 
evidence a potential stand-alone effect of the drug, aside from its effect over L-DOPA 717 
stability; (j, k, l) -L vs -LT treated VMAT2-LO animals were compared to evidence the 718 
effect of stabilizing L-DOPA bioavailability on motor progression. -V vs -T progressions 719 
were not significantly different (t-test on grouped slopes), while -L vs -LT progressions 720 
in the bar test differed significantly (k, unpaired t(8.43)=4.24, **p=.003), with the latter 721 
evidencing practically no worsening of body rigidity in VMAT2-LO (slope of dark line 722 
close to 1) over a 17-week period. (V = vehicle; L = L-DOPA; T = tolcapone; LT = L-723 
DOPA+tolcapone; number of animals: WT-V=5, WT-L=6, WT-T=6, WT-LT=6, LO-724 
V=5, LO-L=5, LO-T=5, LO-LT=6). 725 
 726 
Figure 3. Preserved striatal DAT integrity in VMAT2-LO with stabilized L-DOPA 727 
bioavailability. (a) Analyzed area from coronal sections of striatum from VMAT2-WT 728 
and VMAT2-LO mice. (b) VMAT2-LO-V mice presented reduced DAT immunostaining 729 
strength compared to VMAT2-WT-V controls (Welch’s t(29.86)=2.43, *p=.022). (c) 730 
Individual examples of DAT reactivity in striatum of -V, -L, -T and –LT VMAT2-LO 731 
animals. (d) Statistical analyses of optical-density in differently treated VMAT2-LO 732 
animals show partially rescued DAT levels in VMAT2-LO-LT (one-way ANOVA, 733 
Brown-Forsythe F(3,69)=4.83, V*LT,**p=.004). (V = vehicle; L = L-DOPA; T = 734 
tolcapone; LT = L-DOPA+tolcapone; number of animals: WT-V=5, LO-V=3, LO-L=5, 735 
LO-T=5, LO-LT=6).  736 
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Figure 4. Rigidity correlates with integrity of striatal dopaminergic terminals. (a) 737 
The slope of the robust linear fit on the time of immobility’ scores of each VMAT2-LO 738 
individual over the 17-week treatment, representing the progression of bradykinesia 739 
during the complete intervention (<0 = improvement, >0 = worsening), and DAT optical 740 
density, as a marker of DA striatal terminal integrity, in VMAT2-LO mice correlate 741 
significantly (Pearson’s, r(17)=-0.50, *p=.015, n = 19). (b) Exploratory group-based 742 
clustering for bradykinesia progression (<0 means improvement, >0 means 743 
worsening) and DAT optical density levels for VMAT2-WT-V and VMAT2-LO-V, -L, -T 744 
and -LT groups. (V = vehicle; L = L-DOPA; T = tolcapone; LT = L-DOPA+tolcapone; 745 
number of animals: WT-V=5, LO-V=3, LO-L=5, LO-T=5, LO-LT=6). 746 
 747 
Figure 5. Effects on food intake, tHcy plasma levels and hepatic enzymes. (a) 748 
Food intake was evaluated on protocol-week 15 for VMAT2-LO (n = 21) and VMAT2-749 
WT (n = 23) mice. Ingested food per body weight was calculated for each group: no 750 
differences between treatments within genotypes were observed (two-way ANOVA, 751 
F(3,37)=0.19, genotype*treatment interaction, p=.906). However, when pulling 752 
together all animals of the same genotype, regardless of the treatment, VMAT2-LO 753 
animals show increased feeding behavior (two-way ANOVA, F(1,37)=18.36, genotype 754 
main effect, ***p<.001) when compared to VMAT2-WT mice. Number of animals: WT-755 
V=5, WT-L=6, WT-T=6, WT-LT=6, LO-V=5, LO-L=5, LO-T=5,  LO-LT=6. (b) Increased 756 
tHcy plasma levels observed upon L-DOPA treatment were normalized by combined 757 
L-DOPA+tolcapone (one-way ANOVA F(3,18)=3.49, *p=.037; Tuckey multiple-758 
comparisons: V*L, *p=.038;  V*LT , p=.865). Shadow indicates normal plasma tHcy 759 
levels (< 6 µmol/L) in male C57BL/6J mice. Number of animals: WT-V=5, WT-L=6, 760 
WT-T=6, WT-LT=6. (c) Alanine transaminase (ALT) and aspartate transaminase 761 
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(AST), marker enzymes of functional liver integrity, were determined in -V and –LT 762 
VMAT2-LO mice. No differences were observed between treatments (ALT, V*LT, 763 
unpaired t(7)=1.49, p=.179; AST, V*LT, unpaired t(7)=0.40, p=.703). Number of 764 
animals: LO-V=5, LO-LT=4. (d) The ratio of AST/ALT was determined to also be 765 
normal (AST/ALT ratio, V*LT, unpaired t(7)=0.98, p=.359). V = vehicle; L = L-DOPA; 766 
T = tolcapone; LT = L-DOPA+tolcapone. 767 
